Catalog No.
DHJ62204
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NP84
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
RO-5458640, RO 5458640, RO5458640
Clone ID
RO-5458640
TWEAK increases angiogenesis to promote diabetic skin wound healing by regulating Fn14/EGFR signaling., PMID:39166480
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma., PMID:38582787
TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease., PMID:34155062
Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B., PMID:32958685
Tumor Necrosis Factor (TNF) Receptor Expression Determines Keratinocyte Fate upon Stimulation with TNF-Like Weak Inducer of Apoptosis., PMID:31885495
A single molecule assay for ultrasensitive detection of Fn14 in human serum., PMID:31580829
A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis., PMID:31395500
Biomeasures and mechanistic modeling highlight PK/PD risks for a monoclonal antibody targeting Fn14 in kidney disease., PMID:29190188
TWEAK/Fn14 signaling in tumors., PMID:28639899
Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease., PMID:28636775
Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells., PMID:28357912
TWEAK/Fn14 Activation Contributes to the Pathogenesis of Bullous Pemphigoid., PMID:28351660
Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins., PMID:28095113
Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis., PMID:27786399
Out of the TWEAKlight: Elucidating the Role of Fn14 and TWEAK in Acute Kidney Injury., PMID:27339384
Fn14: a new player in cancer-induced cachexia., PMID:27254081
The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson's disease., PMID:26808775
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors., PMID:26446946
Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival., PMID:26359988
Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD., PMID:26012567
TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice., PMID:25911200
A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells., PMID:25808356
Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells., PMID:25542792
TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy., PMID:25504044
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC., PMID:25239934
Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis., PMID:24467773
TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization., PMID:24408972
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo., PMID:24135629
Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth., PMID:24130833
Fn14 in podocytes and proteinuric kidney disease., PMID:23999007
The TWEAK-Fn14 system as a potential drug target., PMID:23957828
Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis., PMID:23928094
Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors., PMID:23722548
Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity., PMID:23532848
TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice., PMID:23462911
HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes., PMID:23288170
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment., PMID:23190886
TWEAK signals through JAK-STAT to induce tumor cell apoptosis., PMID:23107828
Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway., PMID:22909796
Role of TWEAK in lupus nephritis: a bench-to-bedside review., PMID:22727560
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models., PMID:22669574
A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interaction., PMID:22644269
TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis., PMID:22314077
TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation., PMID:22278019
Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14)., PMID:22081603
Development of an Fn14 agonistic antibody as an anti-tumor agent., PMID:21697654
Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells., PMID:21586630
Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas., PMID:21483105
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis., PMID:21435232
Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury., PMID:20927042
For research use only. Not for human or drug use.
